share_log

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Addex Therapeutics | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/06/06 05:07

Moomoo AI 已提取核心訊息

Addex Therapeutics reported Q1 2024 financial results with revenue of CHF 0.2M from the Indivior collaboration, down from CHF 0.5M in Q1 2023. Operating costs increased to CHF 1.0M from CHF 0.9M, primarily due to higher legal fees. Net loss from continuing operations was CHF 0.7M compared to CHF 0.4M in Q1 2023.On April 2, 2024, Addex completed the sale of its allosteric modulator drug discovery platform and preclinical portfolio to newly formed Neurosterix Pharma, which received USD 63M funding led by Perceptive Advisors. Addex received CHF 5M cash and retained 20% equity in Neurosterix. The company maintains partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant.Cash and cash equivalents stood at CHF 1.6M as of March 31, 2024, compared to CHF 3.9M at year-end 2023. The company recorded CHF 0.8M in assets held for sale and CHF 1.3M in associated liabilities related to the Neurosterix transaction.
Addex Therapeutics reported Q1 2024 financial results with revenue of CHF 0.2M from the Indivior collaboration, down from CHF 0.5M in Q1 2023. Operating costs increased to CHF 1.0M from CHF 0.9M, primarily due to higher legal fees. Net loss from continuing operations was CHF 0.7M compared to CHF 0.4M in Q1 2023.On April 2, 2024, Addex completed the sale of its allosteric modulator drug discovery platform and preclinical portfolio to newly formed Neurosterix Pharma, which received USD 63M funding led by Perceptive Advisors. Addex received CHF 5M cash and retained 20% equity in Neurosterix. The company maintains partnerships with Janssen and Indivior, along with clinical-stage assets including dipraglurant.Cash and cash equivalents stood at CHF 1.6M as of March 31, 2024, compared to CHF 3.9M at year-end 2023. The company recorded CHF 0.8M in assets held for sale and CHF 1.3M in associated liabilities related to the Neurosterix transaction.
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Dogwood Therapeutics
    DWTX
    -- 13.350
    Transcode Therapeutics
    RNAZ
    -- 5.500
    Evaxion Biotech
    EVAX
    -- 3.640
    Hepion Pharmaceuticals
    HEPA
    -- 0.2000
    Nutriband
    NTRB
    -- 9.900
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    科技巨頭業績季拉開帷幕： 市場將如何反應？
    🎙️ 討論： 1. 大型科技公司的業績能否再次引領各版塊上漲？ 2. 科技巨頭將會如何受到「特朗普因素」的影響？ 展开
    在科技巨頭公佈業績之前，您需要了解的情況